The ASCO Post Podcast - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

The ASCO Post Podcast — Science
The ASCO Post Podcast

News and views from the world of clinical oncology and hematology.

Copyright: © Harborside

Latest Episodes:

2023 ASCO Genitourinary Cancers Symposium: Focus on RCC Feb 24, 2023

Show notes

On this episode, we’re sharing news from our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from two researchers about their findings in renal cell carcinoma (RCC).

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Recent FDA Approvals for Patients With Breast Cancer Feb 14, 2023

Show notes

On this episode, we’re reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Highlights From the 2023 ASCO Gastrointestinal Cancers Symposium Feb 03, 2023

Show notes

The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we’re hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal cancer, gastric cancer, and pancreatic cancer, respectively.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer: In Conversation With The ASCO Post Jan 27, 2023

Show notes

On this episode, Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, Professor of Surgical Oncology and Global Health at University of Nebraska Medical Center, and an editorial advisor for The ASCO Post, holds a conversation with John H. Strickler, MD, a medical oncologist at Duke University Medical Center. The topic is the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS G12C–mutated pancreatic cancer, based on Strickler et al’s paper published on January 5th in The New England Journal of Medicine.

Coverage of stories discussed this week on ascopost.com:

Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

2022 ASH Annual Meeting and Exposition: Focus on Lymphoma Jan 20, 2023

Show notes

On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in lymphoma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

2022 ASH Annual Meeting and Exposition: Focus on Multiple Myeloma Jan 13, 2023

Show notes

On this episode, we’re continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we’ll hear from several researchers about their findings in multiple myeloma.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

2022 ASH Annual Meeting and Exposition: Focus on Leukemia Jan 06, 2023

Show notes

On this episode, we’re featuring authors discussing their impactful research presented at the 2022 ASH Annual Meeting and Exposition, focusing on findings in different subtypes of leukemia.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Highlights From the 2022 San Antonio Breast Cancer Symposium Dec 16, 2022

Show notes

This year’s San Antonio Breast Cancer Symposium took place last week. On this episode, we’re hearing from the authors of three high-impact studies that were presented at the meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

FDA Approvals: November 2022 Dec 02, 2022

Show notes

On this episode, we’re reviewing U.S. Food and Drug Administration (FDA) approvals in oncology and hematology that occurred during the month of November.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Findings From SITC 2022 Nov 18, 2022

Show notes

On this episode, we’re hearing from three authors of high-impact research that was presented at the recent Annual Meeting of the Society for Immunotherapy of Cancer, or SITC. Their studies focused on immune checkpoint inhibitors for patients living with HIV and cancer, T-cell receptor T-cell therapy for patients with solid tumors, and radiation boosts plus pembrolizumab in patients with triple-negative breast cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Related Podcasts